EP3613852A3
(en)
|
2011-07-22 |
2020-04-22 |
President and Fellows of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
WO2013163628A2
(en)
|
2012-04-27 |
2013-10-31 |
Duke University |
Genetic correction of mutated genes
|
EP2931892B1
(en)
|
2012-12-12 |
2018-09-12 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
MX2015007550A
(es)
|
2012-12-12 |
2017-02-02 |
Broad Inst Inc |
Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas.
|
US10760064B2
(en)
|
2013-03-15 |
2020-09-01 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
WO2014204578A1
(en)
|
2013-06-21 |
2014-12-24 |
The General Hospital Corporation |
Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
|
CN110540991B
(zh)
|
2013-03-15 |
2023-10-24 |
通用医疗公司 |
使用截短的引导RNA(tru-gRNA)提高RNA引导的基因组编辑的特异性
|
WO2014204727A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
EP3011034B1
(en)
|
2013-06-17 |
2019-08-07 |
The Broad Institute, Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
|
AU2014281026B2
(en)
|
2013-06-17 |
2020-05-28 |
Massachusetts Institute Of Technology |
Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
|
CN105492611A
(zh)
|
2013-06-17 |
2016-04-13 |
布罗德研究所有限公司 |
用于序列操纵的优化的crispr-cas双切口酶系统、方法以及组合物
|
RU2716420C2
(ru)
|
2013-06-17 |
2020-03-11 |
Те Брод Инститьют Инк. |
Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
US9228207B2
(en)
|
2013-09-06 |
2016-01-05 |
President And Fellows Of Harvard College |
Switchable gRNAs comprising aptamers
|
US9737604B2
(en)
|
2013-09-06 |
2017-08-22 |
President And Fellows Of Harvard College |
Use of cationic lipids to deliver CAS9
|
US20150166982A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting pi3k point mutations
|
WO2015089486A2
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
MX2016007328A
(es)
|
2013-12-12 |
2017-07-19 |
Broad Inst Inc |
Suministro, uso y aplicaciones terapeuticas de sistemas y composiciones crispr-cas para edicion del genoma.
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
AU2014362248A1
(en)
|
2013-12-12 |
2016-06-16 |
Massachusetts Institute Of Technology |
Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders
|
WO2015188065A1
(en)
|
2014-06-05 |
2015-12-10 |
Sangamo Biosciences, Inc. |
Methods and compositions for nuclease design
|
AU2015280069B2
(en)
|
2014-06-23 |
2021-08-12 |
The General Hospital Corporation |
Genomewide unbiased identification of dsbs evaluated by sequencing (guide-seq)
|
US10077453B2
(en)
|
2014-07-30 |
2018-09-18 |
President And Fellows Of Harvard College |
CAS9 proteins including ligand-dependent inteins
|
US11680268B2
(en)
|
2014-11-07 |
2023-06-20 |
Editas Medicine, Inc. |
Methods for improving CRISPR/Cas-mediated genome-editing
|
US20170266320A1
(en)
*
|
2014-12-01 |
2017-09-21 |
President And Fellows Of Harvard College |
RNA-Guided Systems for In Vivo Gene Editing
|
EP3985115A1
(en)
|
2014-12-12 |
2022-04-20 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
US10190106B2
(en)
*
|
2014-12-22 |
2019-01-29 |
Univesity Of Massachusetts |
Cas9-DNA targeting unit chimeras
|
EP3265559B1
(en)
*
|
2015-03-03 |
2021-01-06 |
The General Hospital Corporation |
Engineered crispr-cas9 nucleases with altered pam specificity
|
WO2016182959A1
(en)
|
2015-05-11 |
2016-11-17 |
Editas Medicine, Inc. |
Optimized crispr/cas9 systems and methods for gene editing in stem cells
|
CN106011104B
(zh)
*
|
2015-05-21 |
2019-09-27 |
清华大学 |
利用拆分Cas系统进行基因编辑和表达调控方法
|
WO2016201047A1
(en)
|
2015-06-09 |
2016-12-15 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for improving transplantation
|
WO2016205759A1
(en)
*
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
RU2752834C2
(ru)
*
|
2015-06-18 |
2021-08-09 |
Те Брод Инститьют, Инк. |
Мутации фермента crispr, уменьшающие нецелевые эффекты
|
CA2996001A1
(en)
|
2015-08-25 |
2017-03-02 |
Duke University |
Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases
|
US9926546B2
(en)
|
2015-08-28 |
2018-03-27 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
AU2016319110B2
(en)
|
2015-09-11 |
2022-01-27 |
The General Hospital Corporation |
Full interrogation of nuclease DSBs and sequencing (FIND-seq)
|
AU2016326711B2
(en)
|
2015-09-24 |
2022-11-03 |
Editas Medicine, Inc. |
Use of exonucleases to improve CRISPR/Cas-mediated genome editing
|
JP2018529353A
(ja)
|
2015-09-30 |
2018-10-11 |
ザ ジェネラル ホスピタル コーポレイション |
配列決定法による切断事象の包括的生体外報告(CIRCLE−seq)
|
US11970710B2
(en)
|
2015-10-13 |
2024-04-30 |
Duke University |
Genome engineering with Type I CRISPR systems in eukaryotic cells
|
IL294014B1
(en)
|
2015-10-23 |
2024-03-01 |
Harvard College |
Nucleobase editors and their uses
|
EP3433363A1
(en)
|
2016-03-25 |
2019-01-30 |
Editas Medicine, Inc. |
Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
|
US11236313B2
(en)
|
2016-04-13 |
2022-02-01 |
Editas Medicine, Inc. |
Cas9 fusion molecules, gene editing systems, and methods of use thereof
|
AU2017306676B2
(en)
|
2016-08-03 |
2024-02-22 |
President And Fellows Of Harvard College |
Adenosine nucleobase editors and uses thereof
|
CA3033327A1
(en)
|
2016-08-09 |
2018-02-15 |
President And Fellows Of Harvard College |
Programmable cas9-recombinase fusion proteins and uses thereof
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
CN110462034A
(zh)
*
|
2016-10-07 |
2019-11-15 |
综合Dna技术公司 |
化脓链球菌cas9突变基因和由其编码的多肽
|
CN110214180A
(zh)
|
2016-10-14 |
2019-09-06 |
哈佛大学的校长及成员们 |
核碱基编辑器的aav递送
|
EP3525832A4
(en)
|
2016-10-14 |
2020-04-29 |
The General Hospital Corp. |
SITE SPECIFIC NUCLEASES WITH EPIGENETIC REGULATION
|
US9963719B1
(en)
|
2016-12-05 |
2018-05-08 |
Editas Medicine, Inc. |
Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA
|
US11377645B2
(en)
|
2016-12-16 |
2022-07-05 |
The Rockefeller University |
Compositions and methods using Cas9 with enhanced spacer acquisition function
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
US11873496B2
(en)
|
2017-01-09 |
2024-01-16 |
Whitehead Institute For Biomedical Research |
Methods of altering gene expression by perturbing transcription factor multimers that structure regulatory loops
|
IT201700016321A1
(it)
|
2017-02-14 |
2018-08-14 |
Univ Degli Studi Di Trento |
Mutanti di cas9 ad alta specificita' e loro applicazioni.
|
US11898179B2
(en)
|
2017-03-09 |
2024-02-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
JP2020510439A
(ja)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
シトシンからグアニンへの塩基編集因子
|
KR20190130613A
(ko)
|
2017-03-23 |
2019-11-22 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
|
US20210047633A1
(en)
*
|
2017-03-29 |
2021-02-18 |
Editas Medicine, Inc. |
Selection methods
|
EP3612551A4
(en)
|
2017-04-21 |
2020-12-30 |
The General Hospital Corporation |
VARIANTS OF CPF1 (CAS12A) WITH MODIFIED PAM SPECIFICITY
|
CN108795989A
(zh)
*
|
2017-04-26 |
2018-11-13 |
哈尔滨工业大学 |
SpyCas9的基因编辑活性抑制位点及其抑制剂
|
WO2018201086A1
(en)
|
2017-04-28 |
2018-11-01 |
Editas Medicine, Inc. |
Methods and systems for analyzing guide rna molecules
|
WO2018209320A1
(en)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
|
JP2020521446A
(ja)
|
2017-05-25 |
2020-07-27 |
ザ ジェネラル ホスピタル コーポレイション |
二部塩基エディター(bbe)構造およびii型−c−cas9ジンクフィンガー編集
|
WO2018221685A1
(ja)
|
2017-05-31 |
2018-12-06 |
国立大学法人 東京大学 |
改変されたCas9タンパク質及びその用途
|
US20200140835A1
(en)
*
|
2017-06-06 |
2020-05-07 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 Nucleases
|
AU2018279829B2
(en)
|
2017-06-09 |
2024-01-04 |
Editas Medicine, Inc. |
Engineered Cas9 nucleases
|
CN111133110A
(zh)
*
|
2017-06-15 |
2020-05-08 |
株式会社图尔金 |
用于重复扩增突变的基因组编辑系统
|
US10011849B1
(en)
|
2017-06-23 |
2018-07-03 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
US9982279B1
(en)
|
2017-06-23 |
2018-05-29 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
JP2020530279A
(ja)
*
|
2017-07-07 |
2020-10-22 |
ツールゲン インコーポレイテッドToolgen Incorporated |
標的特異的なcrisprバリアント
|
WO2019014564A1
(en)
|
2017-07-14 |
2019-01-17 |
Editas Medicine, Inc. |
SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES
|
WO2019023680A1
(en)
|
2017-07-28 |
2019-01-31 |
President And Fellows Of Harvard College |
METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE)
|
WO2019040650A1
(en)
*
|
2017-08-23 |
2019-02-28 |
The General Hospital Corporation |
GENETICALLY MODIFIED CRISPR-CAS9 NUCLEASES HAVING MODIFIED PAM SPECIFICITY
|
US11319532B2
(en)
|
2017-08-30 |
2022-05-03 |
President And Fellows Of Harvard College |
High efficiency base editors comprising Gam
|
WO2019049913A1
(ja)
|
2017-09-05 |
2019-03-14 |
国立大学法人 東京大学 |
改変されたCas9タンパク質及びその用途
|
WO2019060469A2
(en)
*
|
2017-09-19 |
2019-03-28 |
Massachusetts Institute Of Technology |
CAS9 STREPTOCOCCUS CANIS AS A GENOMIC ENGINEERING PLATFORM WITH NEW PAM SPECIFICITY
|
JP2021500863A
(ja)
|
2017-09-29 |
2021-01-14 |
インテリア セラピューティクス,インコーポレイテッド |
ゲノム編集用のポリヌクレオチド、組成物および方法
|
TWI833708B
(zh)
|
2017-09-29 |
2024-03-01 |
美商英特利亞醫療公司 |
調配物
|
KR20200058509A
(ko)
|
2017-09-29 |
2020-05-27 |
인텔리아 테라퓨틱스, 인크. |
Attr 아밀로이드증의 ttr 유전자 편집 및 치료를 위한 조성물 및 방법
|
WO2019067999A1
(en)
|
2017-09-29 |
2019-04-04 |
Intellia Therapeutics, Inc. |
IN VITRO METHOD OF ADMINISTERING MRNA USING LIPID NANOPARTICLES
|
CN107630018B
(zh)
*
|
2017-09-30 |
2018-10-12 |
深圳三智医学科技有限公司 |
一种用于编辑或修复hbb基因的试剂盒
|
US11725228B2
(en)
|
2017-10-11 |
2023-08-15 |
The General Hospital Corporation |
Methods for detecting site-specific and spurious genomic deamination induced by base editing technologies
|
US11795443B2
(en)
|
2017-10-16 |
2023-10-24 |
The Broad Institute, Inc. |
Uses of adenosine base editors
|
EP3749754A4
(en)
|
2018-02-08 |
2021-10-20 |
Applied Stemcell, Inc. |
PROCEDURE FOR SCREENING VARIANTS OF A TARGET
|
CN109306361B
(zh)
*
|
2018-02-11 |
2022-06-28 |
华东师范大学 |
一种新的a/t到g/c碱基定点转换的基因编辑系统
|
WO2019161251A1
(en)
*
|
2018-02-15 |
2019-08-22 |
The Broad Institute, Inc. |
Cell data recorders and uses thereof
|
WO2019168953A1
(en)
*
|
2018-02-27 |
2019-09-06 |
President And Fellows Of Harvard College |
Evolved cas9 variants and uses thereof
|
KR102647714B1
(ko)
|
2018-03-19 |
2024-03-18 |
리제너론 파마슈티칼스 인코포레이티드 |
CRISPR/Cas 시스템을 사용한 동물에서의 전사 조절
|
US20210115419A1
(en)
|
2018-03-23 |
2021-04-22 |
Massachusetts Eye And Ear Infirmary |
CRISPR/Cas9-Mediated Exon-Skipping Approach for USH2A-Associated Usher Syndrome
|
US10386703B1
(en)
|
2018-04-03 |
2019-08-20 |
Chandler Evans |
Systems and methods for orbiting imaging
|
JP7486189B2
(ja)
*
|
2018-04-06 |
2024-05-17 |
国立大学法人 東京大学 |
エンジニアリングされたBlCas9ヌクレアーゼ
|
WO2019204378A1
(en)
|
2018-04-17 |
2019-10-24 |
The General Hospital Corporation |
Sensitive in vitro assays for substrate preferences and sites of nucleic acid binding, modifying, and cleaving agents
|
JP2021523739A
(ja)
*
|
2018-05-11 |
2021-09-09 |
ビーム セラピューティクス インク. |
プログラム可能な塩基エディターシステムを用いて単一ヌクレオチド多型を編集する方法
|
CA3101477A1
(en)
*
|
2018-05-30 |
2019-12-05 |
M2X2 Therapeutics, Inc. |
Cell therapy
|
SG11202012228QA
(en)
|
2018-06-08 |
2021-01-28 |
Modalis Therapeutics Corp |
MODIFIED Cas9 PROTEIN AND USE THEREOF
|
CN110684755B
(zh)
*
|
2018-07-05 |
2021-12-31 |
清华大学 |
基于进化信息构建嵌合SaCas9用于增强和扩展PAM位点的识别
|
JP2021524272A
(ja)
|
2018-07-10 |
2021-09-13 |
エーエルアイエー セラピューティクス エス. アール. エル. |
ガイドrna分子および/またはガイドrna分子/rna誘導型ヌクレアーゼ複合体の無痕跡送達のための小胞およびその産生方法
|
JP2021531804A
(ja)
|
2018-07-31 |
2021-11-25 |
インテリア セラピューティクス,インコーポレイテッド |
原発性高シュウ酸尿症1型(ph1)を治療するためのヒドロキシ酸オキシダーゼ1(hao1)遺伝子編集のための組成物および方法
|
WO2020041751A1
(en)
*
|
2018-08-23 |
2020-02-27 |
The Broad Institute, Inc. |
Cas9 variants having non-canonical pam specificities and uses thereof
|
MX2021003457A
(es)
|
2018-09-28 |
2021-07-16 |
Intellia Therapeutics Inc |
Composiciones y métodos para la edición génica de lactato deshidrogenasa (ldha).
|
CA3116132A1
(en)
|
2018-10-16 |
2020-04-23 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunotherapy
|
MX2021004276A
(es)
|
2018-10-18 |
2021-09-08 |
Intellia Therapeutics Inc |
Composiciones y metodos para tratar deficiencia de alfa-1 antitripsina.
|
BR112021007301A2
(pt)
|
2018-10-18 |
2021-07-27 |
Intellia Therapeutics, Inc. |
composições e métodos para expressar fator ix
|
CN114207130A
(zh)
|
2018-10-18 |
2022-03-18 |
英特利亚治疗股份有限公司 |
用于从白蛋白基因座进行转基因表达的组合物和方法
|
BR112021007323A2
(pt)
|
2018-10-18 |
2021-07-27 |
Intellia Therapeutics, Inc. |
construtos de ácido nucleico e métodos para uso
|
US20210246473A1
(en)
|
2018-10-24 |
2021-08-12 |
Modalis Therapeutics Corporation |
Modified cas9 protein, and use thereof
|
US11946040B2
(en)
|
2019-02-04 |
2024-04-02 |
The General Hospital Corporation |
Adenine DNA base editor variants with reduced off-target RNA editing
|
EP3942040A1
(en)
|
2019-03-19 |
2022-01-26 |
The Broad Institute, Inc. |
Methods and compositions for editing nucleotide sequences
|
WO2020198641A2
(en)
|
2019-03-28 |
2020-10-01 |
Intellia Therapeutics, Inc. |
Polynucleotides, compositions, and methods for polypeptide expression
|
WO2020198706A1
(en)
|
2019-03-28 |
2020-10-01 |
Intellia Therapeutics, Inc. |
Compositions and methods for ttr gene editing and treating attr amyloidosis comprising a corticosteroid or use thereof
|
EA202192636A1
(ru)
|
2019-03-28 |
2022-03-17 |
Интеллиа Терапьютикс, Инк. |
Композиции и способы, содержащие гидовую рнк ttr и полинуклеотид, кодирующий днк-связывающий агент, гидируемый рнк
|
EP3953470A1
(en)
|
2019-04-12 |
2022-02-16 |
Astrazeneca AB |
Compositions and methods for improved gene editing
|
MX2021012966A
(es)
*
|
2019-04-25 |
2022-04-06 |
Univ Leland Stanford Junior |
Cas9 diseñado con intervalo de dirección de adn ampliado.
|
US20230022146A1
(en)
|
2019-06-17 |
2023-01-26 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
|
JP2022539569A
(ja)
*
|
2019-07-03 |
2022-09-12 |
ザ チルドレンズ メディカル センター コーポレーション |
遺伝子置換のための組成物および方法
|
CN110257427B
(zh)
*
|
2019-07-22 |
2021-01-22 |
青岛农业大学 |
无PAM限制的CRISPR/Cas9系统及其应用
|
CN110577969B
(zh)
*
|
2019-08-08 |
2022-07-22 |
复旦大学 |
CRISPR/Sa-SlugCas9基因编辑系统及其应用
|
EP4022057A1
(en)
|
2019-08-27 |
2022-07-06 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of disorders associated with repetitive dna
|
CA3153980A1
(en)
|
2019-09-13 |
2021-03-18 |
Regeneron Pharmaceuticals, Inc. |
Transcription modulation in animals using crispr/cas systems delivered by lipid nanoparticles
|
LT3812472T
(lt)
|
2019-10-21 |
2023-03-10 |
Albert-Ludwigs-Universität Freiburg |
Objektyviai nešališkas tyrimas in vitro sąlygomis, skirtas vienos arba daugiau tikslinių programuojamų nukleazių ląstelėje nespecifinės sąveikos aktyvumui profiliuoti (abnoba-seq)
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
EP4077674A1
(en)
|
2019-12-18 |
2022-10-26 |
Alia Therapeutics S.R.L. |
Compositions and methods for treating retinitis pigmentosa
|
US20210284978A1
(en)
*
|
2020-01-24 |
2021-09-16 |
The General Hospital Corporation |
Unconstrained Genome Targeting with near-PAMless Engineered CRISPR-Cas9 Variants
|
EP4093863A4
(en)
*
|
2020-01-24 |
2024-04-10 |
The General Hospital Corporation |
CRISPR-CAS ENZYMES WITH IMPROVED ON-TARGET ACTIVITY
|
GB2594339B
(en)
*
|
2020-02-14 |
2023-02-08 |
Metagenomi Inc |
Enzymes with RUVC domains
|
CN115667283A
(zh)
*
|
2020-03-03 |
2023-01-31 |
小利兰斯坦福大学董事会 |
Rna指导的千碱基规模基因组重组工程
|
US20230102342A1
(en)
|
2020-03-23 |
2023-03-30 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
|
MX2022012110A
(es)
|
2020-03-31 |
2022-10-18 |
Metagenomi Inc |
Sistemas crispr clase ii tipo ii.
|
MX2022014008A
(es)
|
2020-05-08 |
2023-02-09 |
Broad Inst Inc |
Métodos y composiciones para la edición simultánea de ambas cadenas de una secuencia de nucleótidos de doble cadena objetivo.
|
CN112159801B
(zh)
*
|
2020-07-13 |
2022-11-15 |
复旦大学 |
SlugCas9-HF蛋白、含有SlugCas9-HF蛋白的基因编辑系统及应用
|
WO2022018638A1
(en)
|
2020-07-21 |
2022-01-27 |
Crispr Therapeutics Ag |
Genome-editing compositions and methods to modulate faah for treatment of neurological disorders
|
JP2022037603A
(ja)
*
|
2020-08-25 |
2022-03-09 |
国立大学法人 東京大学 |
エンジニアリングされたCjCas9タンパク質
|
WO2022056000A1
(en)
|
2020-09-09 |
2022-03-17 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of duchenne muscular dystrophy
|
JP2023541400A
(ja)
|
2020-09-11 |
2023-10-02 |
ライフエディット セラピューティクス,インコーポレイティド |
Dna修飾酵素並びにその活性断片及びバリアント並びにその使用方法
|
WO2022092317A1
(ja)
*
|
2020-10-30 |
2022-05-05 |
国立大学法人東京大学 |
エンジニアリングされたCas12fタンパク質
|
WO2022120022A1
(en)
|
2020-12-02 |
2022-06-09 |
Regeneron Pharmaceuticals, Inc. |
Crispr sam biosensor cell lines and methods of use thereof
|
CN112553246A
(zh)
*
|
2020-12-08 |
2021-03-26 |
安徽省农业科学院水稻研究所 |
一种基于CRISPR-SaCas9系统的高效基因组编辑载体及其应用
|
CN112430613A
(zh)
*
|
2020-12-08 |
2021-03-02 |
安徽省农业科学院水稻研究所 |
一种宽编辑范围的SpG基因及其应用
|
WO2022125982A1
(en)
|
2020-12-11 |
2022-06-16 |
Intellia Therapeutics, Inc. |
Compositions and methods for reducing mhc class ii in a cell
|
TW202237845A
(zh)
|
2020-12-11 |
2022-10-01 |
美商英特利亞醫療公司 |
用於涉及去胺作用之基因體編輯之多核苷酸、組合物及方法
|
CA3205138A1
(en)
|
2020-12-17 |
2022-06-23 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
|
KR20230135068A
(ko)
|
2020-12-23 |
2023-09-22 |
인텔리아 테라퓨틱스, 인크. |
세포에서 ciita를 유전적으로 변형시키기 위한 조성물및 방법
|
TW202239959A
(zh)
|
2020-12-23 |
2022-10-16 |
美商英特利亞醫療公司 |
用於減少細胞中hla-a之組合物及方法
|
CA3206484A1
(en)
|
2020-12-30 |
2022-07-07 |
Intellia Therapeutics, Inc. |
Engineered t cells
|
WO2022152746A1
(en)
|
2021-01-13 |
2022-07-21 |
Alia Therapeutics Srl |
K526d cas9 variants and applications thereof
|
AU2022213505A1
(en)
*
|
2021-02-01 |
2023-09-07 |
Epsilen Bio S.R.L. |
Gene silencing
|
JP2024506016A
(ja)
|
2021-02-08 |
2024-02-08 |
インテリア セラピューティクス,インコーポレイテッド |
免疫療法のためのt細胞免疫グロブリン及びムチンドメイン3(tim3)組成物及び方法
|
WO2022170194A2
(en)
|
2021-02-08 |
2022-08-11 |
Intellia Therapeutics, Inc. |
Lymphocyte activation gene 3 (lag3) compositions and methods for immunotherapy
|
JP2024505672A
(ja)
|
2021-02-08 |
2024-02-07 |
インテリア セラピューティクス,インコーポレイテッド |
免疫療法のためのナチュラルキラー細胞受容体2b4組成物及び方法
|
TW202300649A
(zh)
|
2021-03-22 |
2023-01-01 |
美商生命編輯治療學公司 |
Dna修飾酶及活性片段及其變體及使用方法
|
WO2022238958A1
(en)
|
2021-05-12 |
2022-11-17 |
Crispr Therapeutics Ag |
Multiplex gene editing
|
TW202327626A
(zh)
|
2021-06-22 |
2023-07-16 |
美商英特利亞醫療公司 |
用於體內編輯肝臟基因之方法
|
CA3226002A1
(en)
*
|
2021-06-29 |
2023-01-05 |
Council Of Scientific & Industrial Research |
Engineered fncas9 and uses thereof
|
EP4370698A1
(en)
*
|
2021-07-13 |
2024-05-22 |
Duke University |
Compositions for and methods of improving viral vectors
|
WO2023018637A1
(en)
|
2021-08-09 |
2023-02-16 |
Vertex Pharmaceuticals Incorporated |
Gene editing of regulatory elements
|
EP4392060A1
(en)
|
2021-08-24 |
2024-07-03 |
Intellia Therapeutics, Inc. |
Programmed cell death protein 1 (pd1) compositions and methods for cell-based therapy
|
WO2023081200A2
(en)
|
2021-11-03 |
2023-05-11 |
Intellia Therapeutics, Inc. |
Cd38 compositions and methods for immunotherapy
|
WO2023086847A1
(en)
|
2021-11-10 |
2023-05-19 |
Encodia, Inc. |
Methods for barcoding macromolecules in individual cells
|
CA3238939A1
(en)
|
2021-12-08 |
2023-06-15 |
Gaurang Patel |
Mutant myocilin disease model and uses thereof
|
WO2023159136A2
(en)
|
2022-02-18 |
2023-08-24 |
Dana-Farber Cancer Institute, Inc. |
Epitope engineering of cell-surface receptors
|
WO2023185697A2
(en)
|
2022-03-29 |
2023-10-05 |
Accuredit Therapeutics (Suzhou) Co., Ltd. |
Compositions and methods for treatment of transthyretin amyloidosis
|
WO2023205606A1
(en)
|
2022-04-18 |
2023-10-26 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for enhancing aav therapy and decreasing tropism of aav to the liver
|
WO2023245113A1
(en)
|
2022-06-16 |
2023-12-21 |
Intellia Therapeutics, Inc. |
Methods and compositions for genetically modifying a cell
|
WO2024006955A1
(en)
|
2022-06-29 |
2024-01-04 |
Intellia Therapeutics, Inc. |
Engineered t cells
|
WO2024042489A1
(en)
|
2022-08-25 |
2024-02-29 |
LifeEDIT Therapeutics, Inc. |
Chemical modification of guide rnas with locked nucleic acid for rna guided nuclease-mediated gene editing
|
WO2024061296A2
(en)
|
2022-09-22 |
2024-03-28 |
Accuredit Therapeutics (Suzhou) Co., Ltd. |
Compositions and methods for treatment of hypercholesterolemia and/or cardiovascular disease
|
WO2024095245A2
(en)
|
2022-11-04 |
2024-05-10 |
LifeEDIT Therapeutics, Inc. |
Evolved adenine deaminases and rna-guided nuclease fusion proteins with internal insertion sites and methods of use
|
WO2024123789A1
(en)
|
2022-12-07 |
2024-06-13 |
Sanofi |
Predicting indel frequencies
|